Effects of Transcranial Direct Current Stimulation (tDCS) on Motor Function in Schizophrenia Patients and Individuals at Risk for Psychotic Onset

NCT ID: NCT04086160

Last Updated: 2023-03-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-22

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purposes of this research are to investigate (1) if schizophrenia patients and at-risk individuals present bradykinesia and dyskinesia and (2) if tDCS improves motor performance in schizophrenia patients and at-risk individuals. The first hypothesis is that both schizophrenia patients and at-risk individuals show bradykinesia and dyskinesia, and the motor symptoms are more severe in the former than the latter. The second hypothesis is that tDCS improves motor performance in schizophrenia patients and at-risk cases.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Psychosis Parkinsonism Dyskinesias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

schizophrenia- tDCS

Group Type EXPERIMENTAL

Transcranial direct current stimulation device (Soterix Medical, New York, NY)

Intervention Type DEVICE

Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.

schizophrenia- sham

Group Type SHAM_COMPARATOR

Transcranial direct current stimulation device (Soterix Medical, New York, NY)

Intervention Type DEVICE

Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.

at risk- tDCS

Group Type EXPERIMENTAL

Transcranial direct current stimulation device (Soterix Medical, New York, NY)

Intervention Type DEVICE

Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.

at risk- sham

Group Type SHAM_COMPARATOR

Transcranial direct current stimulation device (Soterix Medical, New York, NY)

Intervention Type DEVICE

Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.

healthy controls for schizophrenia- tDCS

Group Type EXPERIMENTAL

Transcranial direct current stimulation device (Soterix Medical, New York, NY)

Intervention Type DEVICE

Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.

healthy controls for schizophrenia- sham

Group Type SHAM_COMPARATOR

Transcranial direct current stimulation device (Soterix Medical, New York, NY)

Intervention Type DEVICE

Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.

healthy controls for at risk- tDCS

Group Type EXPERIMENTAL

Transcranial direct current stimulation device (Soterix Medical, New York, NY)

Intervention Type DEVICE

Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.

healthy controls for at risk- sham

Group Type SHAM_COMPARATOR

Transcranial direct current stimulation device (Soterix Medical, New York, NY)

Intervention Type DEVICE

Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcranial direct current stimulation device (Soterix Medical, New York, NY)

Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* a diagnosis of schizophrenia without other psychiatric diseases
* having stable psychotic symptoms
* a score of 22 or above in Hong Kong version Montreal Cognitive Assessment
* having no neurological diseases and no medical conditions that affect motor performance


* a score of nine or above in the Chinese version of the 16-item Prodromal Questionnaire (CPQ-16)
* a score of 22 or above in Hong Kong version Montreal Cognitive Assessment
* having no diagnosis of psychiatric diseases
* having no neurological diseases and no medical conditions that affect motor performance


* a score less than nine in CPQ-16
* a score of 22 or above in Hong Kong version Montreal Cognitive Assessment
* having no diagnosis of psychiatric diseases
* having no neurological diseases and no medical conditions that affect motor performance.
Minimum Eligible Age

12 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dr WANG Shumei

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr WANG Shumei

Assistant Professor

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hong Kong Polytechnic University

Kowloon, , Hong Kong

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Hong Kong

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Shu-Mei Wang, PhD

Role: CONTACT

852-27664197

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Shu-Mei Wang, PhD

Role: primary

852-27664197

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HSEARS20190518001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.